Purpose. The aim of this study was to assess if use of the b LACTA test (BLT) for extended-spectrum beta-lactamase (ESBL) detection and/or early bacterial identification by mass spectrometry (MALDI-TOF MS) improves therapeutic decision-making when combined with advice from the antimicrobial stewardship team (AMST) for the management of Gram-negative bacillary (GNB) bacteraemia.
INTRODUCTION
The use of broad-spectrum antibiotics contributes to the emergence of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) [1] and, consequently, carbapenem consumption. Uncontrolled carbapenem use has favoured the emergence of carbapenemase-producing Enterobacteriaceae (CPE), leading to endemicity and major public health care challenges [2] . In light of this, physicians want to reduce unnecessary carbapenem use, as carbapenems are still the mainstay of empirical treatment for bloodstream infections (BSI) suspected to be caused by ESBL-E.
In BSI, both rapid bacterial identification and antimicrobial susceptibility testing are of key importance, particularly in the more severe cases [3] . Several methods have been developed recently to speed up identification and determination of susceptibility of Enterobacteriaceae. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) allows rapid identification either directly from a positive blood culture [4] or after 2-4 h of subculture on solid media, with more than 90 % success rates in the latter case [5, 6] . For the detection of ESBL production in Enterobacteriaceae, chromogenic tests directly of positive blood cultures have been developed [7] . The b LACTA test (Bio-Rad, Marnes-La-Coquette, France) (BLT) is a new chromogenic test that allows rapid detection of resistance to third-generation cephalosporins among isolates of Enterobacteriaceae [8] . Recently, we have shown that this test performed on solid-medium cultures incubated for 3 h, after inoculation with positive blood cultures, is efficient in the detection of ESBL-producing Enterobacteriaceae [9] . In that study, the b LACTA test had a sensitivity of 84.8 %, a specificity of 100 %, a positive predictive value of 100 % and a negative predictive value of 94.0 % for the detection of third-generation cephalosporin (3GC)-resistant Enterobacteriaceae [9] . Thus, routine application of rapid diagnostic tests for ESBL-E detection should lead to improved antimicrobial management, particularly by reducing inappropriate use of carbapenems.
Recent studies have shown a positive impact on clinical management of patients with BSI when rapid bacterial identification by MALDI-TOF MS is used in conjunction with advice from an antimicrobial stewardship team (AMST) [10, 11] . In contrast, the impact of rapid detection of ESBL production directly from positive blood cultures on antibiotic treatment has not been evaluated.
The main aim of this study was to assess the impact of MALDI-TOF MS (option H) and of MALDI-TOF MS+b LACTA test (option A) on AMST's current standard choice of therapy based on Gram-stain results. The secondary aim was to assess the impact of both options on AMST's current standard choice of therapy in terms of escalation, de-escalation and carbapenem prescription.
METHODS Patients
We prospectively analysed GNB-positive blood cultures from patients over a 6-month period (1 March-31 August 2015) at the Hôpital Europ een Georges Pompidou, a French 830-bed acute-care teaching hospital with an average of 30 000 admissions per year. For each patient, only one episode of GNB bacteraemia was included. The following data were recorded for each patient: age, gender, ESBL-E carriage (based solely on prior culture results), nosocomial or community-acquired BSI (nosocomial was defined as BSI after 48 h of hospitalization or acquired in a skilled nursing facility), recent antimicrobial therapy (in the 3 preceding months), severe sepsis or septic shock (according to international definitions) [12] , intensive care unit (ICU) admission, mono-or polymicrobial bacteraemia and source of infection.
Routine microbiological blood testing and laboratory setting The microbiology laboratory operates daily from 07.00 to 19.00 Positive blood cultures were detected using the BacT/ ALERT system (bioM erieux, La Balme-les-Grottes, France).
Gram-stain of all positive blood cultures was performed immediately. The physician in charge was immediately informed of a GNB-positive blood culture and was asked if the patient was already under antimicrobial treatment. Having knowledge of the positive blood culture, he was asked which antimicrobial therapy he would introduce (or continue). At that point an AMST physician gave advice for antimicrobial therapy without knowledge of MALDI-TOF MS or BLT results but knowing the clinical and microbiological history of the patient. Then 3 h later, when he knew the results of both tests, he re-visited the patient and validated or amended the antimicrobial treatment. This approach, option A, was assessed comparatively with a hypothetical option, option H, where AMST would have proposed an antimicrobial treatment while knowing only the clinical status of the patient and the MALDI-TOF MS result. MS and BLT were performed simultaneously on 3 h subcultures, obtained on solid medium, of the positive blood cultures as previously described [9] . MALDI-TOF MS and BLT were performed once every day in the morning, 7/7. The MALDI-TOF MS results were analysed using the Biotyper 3.1.2 software (Bruker Daltonics) according to the manufacturer's recommendations. The AMST received realtime notification of the Gram-stain result, followed 3 h later by the MALDI-TOF MS and BLT results.
Polymicrobial bacteraemia was defined as the isolation of more than one micro-organism during a single BSI episode, except when the second micro-organism was a coagulasenegative staphylococcus. Bacteraemia was considered to be hospital-acquired when blood cultures were taken 48 h after hospitalization. A previous ESBL-E carriage was recorded according to the hospital infection control database. Patients for whom there were no MALDI-TOF MS and/or BLT results were not included in the analysis.
Antimicrobial stewardship team and antibiotic policy An AMST was set up in the hospital at opening in 2000 that is comprised of three infectious disease physicians, a professor, an assistant and at least one resident. The team is integrated in the Microbiology Department and works directly with the microbiologists. The AMST advises clinicians in each episode of BSI by relaying the results of the Gram-stain and providing treatment recommendations. The local antibiotic policy is laid down in consensus guidelines that are based on international, national and local recommendations. Prevalence of antimicrobial resistance is recorded for all strains isolated, including ESBL-E and carbapenemase-producing organisms. Because of the low prevalence of ESBL-E and only exceptional cases of colonization with CPE in our hospital, treatment with third-generation cephalosporins (cefotaxime) is the empirical first choice for infections with non-AmpCproducing Enterobacteriaceae, except in patients known to be previous ESBL-E carriers and in patients with severe sepsis or neutropenia. Piperacillin-tazobactam is used for neutropenic patients and patients in shock whereas cefepime is used when catheter-related bacteraemia is suspected, because of the high prevalence of AmpC-overproducing Enterobacteriaceae in this type of infection in our hospital. Carbapenems are chosen and considered to be adequate for patients known to be ESBL-E carriers, to have severe sepsis or to be in septic shock, with risk factors for ESBL-E infection (known ESBL-E carriage, antimicrobial therapy in the preceding 3 months, residence in a skilled nursing facility (or equivalent) and travel in an ESBL-E-endemic country in the preceding 6 months). Ceftazidime is recommended in case of suspected Pseudomonas spp infection.
Comparison of options for therapeutic decision-making
In our institution, AMST, informed of the Gram-stain results, gives advice for each episode of positive blood culture, which is the gold standard for therapeutic advice in this study.
To assess the impact of BLT, we prospectively evaluated, by comparison against the gold standard, the hypothetical option H (antimicrobial therapy that would have been prescribed following AMST advice informed only of the MALDI-TOF MS results) and the actually implemented option A (antimicrobial therapy that was prescribed with additional knowledge of the b LACTA test results) (Fig. 1 ).
The effectiveness of empirical antimicrobial therapy was evaluated with respect to the antibiotic susceptibility test (AST) results. The antimicrobial therapy initiated by the treating physician was defined as efficient when at least one antibiotic was active against the bacterium responsible for the BSI, even if its spectrum was too broad. In contrast, antimicrobial therapy was defined as not efficient when its spectrum did not include the bacterium responsible for the BSI. Concerning ESBL-E-related bacteraemia, utilization of the association of beta lactam/beta-lactamase inhibitor combinations or of cefoxitin as empirical therapy was considered efficient when the bacterium was susceptible according to the AST result and the patient not in shock. Narrowing (de-escalation) was defined as the change toward a narrower-spectrum antibiotic and broadening (escalation) was defined as the change toward a broader-spectrum antibiotic (e.g. cefotaxime to cefepime) as proposed by Weiss et al. [13] . who has defined a consensual ranking of b-lactams according to both their spectrum and their resistance-promoting potential (Table S1 , available in the online version of this article).
Appropriate prescription of carbapenem was defined as that of a carbapenem prescribed empirically for a patient with risk factors for ESBL-E-related infection. Effectiveness of carbapenem was defined as that of a carbapenem prescribed empirically for a patient with an infection caused by an exclusively carbapenem-suceptible ESBL-E. In contrast, inappropriate carbapenem prescription was defined as that of a carbapenem prescribed empirically for a patient without risk factors for ESBL-E-related infection. Non-effectiveness of carbapenem was defined that of a carbapenem prescribed empirically for a patient infected with bacteria susceptible to effective antibiotics other than carbapenems.
The primary outcome was the comparative impact of MALDI-TOF MS (option H) and MALDI-TOF MS+b LACTA test (option A) on AMST's current standard choice of therapy based on Gram-stain results in terms of antimicrobial activity. The secondary outcome was the impact of both options on AMST's current standard choice of therapy 
in terms of escalation, de-escalation and carbapenem prescription. The observational, theoretical, non-interventional design of this study was in accordance with the standards of our local ethics committee.
Statistics
Categorical variables were compared using the 2 test or Fisher's exact test when appropriate; continuous variables were compared using the Mann-Whitney U test. For qualitative variables, the number of observations and percentage values are provided. Statistical analyses were performed using R version 3.0.2 software.
RESULTS

Patients and infections
A total of 340 patients with GNB-positive blood cultures were identified during the study period, and 131 were included in the final analysis (Fig. 1, Table 1 ). Among the 131 episodes of BSI, only 9 (7 %) were polymicrobial. In total, 69 patients (53 %) had received recent antimicrobial therapy and 14 were previous ESBL-E carriers (11 %). Significantly more of the latter acquired ESBL-E-related bacteraemia than non-carriers (6/14 vs 5/117; P=0.0002) ( Table 1) . Overall, 77 episodes (59 %) were nosocomial. Urinary tract and intravascular catheters were the main sources of bacteraemia (38 and 30 %, respectively). Before blood culture results were available, 91 (69 %) patients received an efficient antimicrobial therapy. Among the remaining 40 patients, 38 received no antibiotic. The antimicrobial therapy prescribed for each option is summarized in Table S1 .
Pathogens
In the 122 episodes of monomicrobial bacteraemia, Enterobacteriaceae were documented in 100 episodes (82 %). Escherichia coli and Klebsiella pneumoniae were predominant (51 and 14 %, respectively). Non-fermentative bacteria were isolated in 18 episodes (15 %) including 15 cases of Pseudomonas aeruginosa ( Table 2) .
Impact of option H and option A on AMST's current standard choice of therapy in terms of antimicrobial activity AMST advice knowing Gram-stain results (gold standard) led to a better rate of efficient antimicrobial therapy than the decision of the physician in charge informed of GNB bacteraemia (121/131 versus 110/131 respectively, P=0.05, data not shown). Compared to gold standard, options H and A did not lead to a better rate of efficient antimicrobial therapy (P=1 and 0.81, respectively) ( Table 3) . Moreover, there was not significant difference between options H and A (120/131 and, 123/131 P=0.63; data not shown).
Impact of option H and option A on AMST's current standard choice of therapy in terms of escalation and de-escalation
There was no difference in terms of escalation or de-escalation between options H and A (5/131 vs 9/131, P=0.41, for escalation and 18/131 vs 19/131, P=1, for de-escalation; data not shown) ( Table 3) . Option A, with respect to option H, led to antimicrobial therapy modification in nine episodes. In seven of these episodes, BLT was positive, which led to the prescription of a carbapenem. In two of the seven episodes, BLT was false-positive due to K. oxytoca, which led to inadequate (unnecessary) prescription of a carbapenem, while in five episodes a positive BLT justified broadening of the antibiotic spectrum with a carbapenem to gain activity against the causative pathogen (one AmpC-overproducing E. cloacae with impermeability of the outer membrane, one ESBL-producing E. coli, two ESBL-producing E. cloacae and one ESBL-producing C. freundii).
Impact of options H and A on AMST's current standard choice of therapy in terms of carbapenem prescriptions
The impact of options H and A in terms of carbapenem prescription is summarized in Table 3 . There was no significant difference in terms of carbapenem prescription between the gold standard and options H and A, respectively (Table 3) . There was also no significant difference in terms of carbapenem prescription between options H and A (6/131 and 12/ 131, respectively, P=0.22; data not shown). There was also no significant difference between both options in terms of effectiveness of carbapenem prescription (6/6 vs 11/12, respectively, P=1; data not shown). Similarly, there was no significant difference between the gold standard and options H and A, respectively, in terms of appropriateness carbapenem prescription (Table 3) . However, there was a significant difference between option H and option A in terms of Severe sepsis/septic shock n (%) 29 (22) ICU* admission n (%) 20 (15) Previous ESBL carriage n (%) 14 (10) ESBL-E BSI with previous ESBL carriage n (%) 6/14 (43)
ESBL-E BSI without previous ESBL carriage n (%) 5/117 (4)
Polymicrobial bacteraemia n (%) 9 (7) Source of infection Urinary tract n (%) 50 (38)
Catheter n (%) 39 (30)
Digestive tract n (%) 24 (18) Lung n (%) 6 (5) Other n (%) 12 (9) *Nosocomial, hospital-acquired and healthcare-associated; ICU, intensive care unit. 
Analytical performance of BLT
The analytical BLT performance for detection of 3GC-resistant Enterobacteriaceae was 85.71 % for sensibility, 96.55 % for specificity, 76.47 % for positive predictive value and 98.25 % for negative predictive value, respectively.
Analytical performances for detection of ESBL-E producers, AmpC-overproducing Enterobacteriaceae and polymicrobial bacteraemia are given in Table S2 .
DISCUSSION
In this prospective, observational study of 131 episodes of Gram-negative bacteraemia, we found that option A and option H, compared to standard AMST advice alone, did Results are given as n (%).
Empirical antimicrobial therapy: EAT.
Gold standard: EAT prescribed by AMST based on the Gram-stain result.
Option H: gold standard+MALDI TOF MS result.
Option A: option H+BLT result.
For the gold standard: escalated or de-escalated is compared to the choice of the physician in charge.
For option H: escalated or de-escalated is compared to the gold standard. For option A: escalated or de-escalated is compared to the gold standard. not lead to a significant modification of antimicrobial therapy and did not allow an optimization of carbapenem prescription.
Concerning BSI, if Gram-staining remains the reference test for guiding routine management [14] , it has been shown that rapid availability of more detailed microbiological results was associated with a positive impact on antimicrobial treatment and hence patient outcome and optimization of cost-effectiveness [15] [16] [17] . Rapid bacterial identification with MALDI-TOF MS in blood cultures combined with advice from AMST, has demonstrated a positive impact on the optimization of antimicrobial therapy, particularly in cases of GNB bacteraemia [10] . Clerc et al. have previously shown the interest of taking MALDI-TOF MS results and AMST advice, as opposed to Gram-stain results only, into account for the clinical management of patients with Gramnegative bacteraemia [10] . Doing so, in this study, MALDI-TOF MS results and AMST advice had a positive impact on more than one-third of episodes of empirical therapy. Other studies have shown that similar considerations reduce the time to antimicrobial optimization, length of hospital stay [11, 18] and mortality [11, 19] . However, bacterial identification by MALDI-TOF MS should be interpreted with caution in cases of polymicrobial bacteraemia. In this study, MALDI-TOF MS results led to a modification of antimicrobial therapy in three episodes that turned out to be inadequate due to polymicrobial bacteraemia.
The b LACTA test has been validated previously for the detection of 3GC resistance in Enterobacteriaceae [8] and ceftazidime resistance in P. aeruginosa [20] but it has not been evaluated in clinical practice. In this study, negative BLT results prompted inadequate antimicrobial therapy in two episodes of cephalosporinase-overproducing Enterobacteriaceae that had not been detected by BLT, a known shortcoming of the test [8, 21, 22] . Renvois e et al. have reported a lower sensitivity of the test in detecting cephalosporin resistance in chromosome-encoded AmpC-overproducing Enterobacteriaceae (67.4 %) than in ESBL-E (96 %) [8] .
Rare false-positive BLT results have been reported previously [8] . Here we obtained similar results for three strains, one high-level penicillinase-producing E. coli, one fully susceptible and one high-level chromosome-encoded betalactamase-producing K. oxytoca. In the two episodes of K. oxytoca, this led to unjustified carbapenem prescription. In the case of the E. coli strain producing a high-level of penicillinase, treatment with cefotaxime was not changed since the source of the sepsis was detected in a BLT-positive urine culture with the corresponding antibiogram.
Prescribing a carbapenem empirically to every patient with healthcare-associated or suspected BSI may be questionable and would likely select for CPE on a broad scale, a potentially detrimental event. Only less than 25 % of the healthcare-associated infections diagnosed in ICU patients colonized with ESBL-E are due to ESBL-E [23] . A recent Dutch study found that less than 10 % of patients admitted to hospital from home were colonized with ESBL-E and that the incidences of nosocomial infections caused by ESBLproducing bacteria were 45.5/10 000 and 2.1/10 000 admission days for carriers and non-carriers, respectively [24] . In this study almost 50 % of previous ESBL-E carriers developed ESBL-E-related BSI. In light of this, wide use of BLT should be beneficial (i), if negative, to avoid systematic carbapenem use in previous ESBL-E carriers and in patients with nosocomial infections and severe sepsis or in septic shock, thereby reducing carbapenem consumption and (ii), if positive, to optimize the antibiotic treatment.
Concerning the prescription of an efficient initial antimicrobial therapy, we did not find any difference between options H and A versus the gold standard at our institution. This might be explained by the long experience of over 15 years of our AMST in BSI management. In this situation only marginal improvement of BSI management could be expected by taking the MALDI-TOF MS and BLT results into account. For the same reason, regarding carbapenem prescription, BLT associated with AMST and MALDI-TOF MS results did not improve significantly the effectiveness of prescription compared to AMST advice alone. If BLT seems unuseful in an institution with an AMST, it should arguably be of greater interest in an institution without AMST, to assist non-infectious disease physicians in deciding on empirical therapy and in avoiding inappropriate carbapenem prescription, particularly in the context of the emergence of antibiotic resistance. In this context, Goodman et al. have developed a clinical decision tree to predict whether a patient with BSI is infected with an ESBL-E [25] . BLT should be associated with this kind of decision tree in a study to explore if the results obtained lead to an improvement of empirical antimicrobial prescription.
Our study has some limitations. First, it was observational, monocentric, carried out in a country of low-incidence of ESBL-E and in an institution where MALDI-TOF MS and BLT are included in the routine analysis of positive blood cultures. For these reasons our results are not generalizable [9, 26] . Second, only cases managed early in the morning, with information on MALDI-TOF MS and BLT results as well as advice from the AMST, were included since MS and BLT are currently not performed in the afternoon. This explains why only one-third of GNB-related BSI has been included. However, this study design reflects the routine clinical management of all episodes of bacteraemia in our hospital and in most hospitals in Paris. Third, with only 11 episodes of BSI caused by ESBL-E, this study may have been underpowered to detect a significant impact of BLT. Fourth, we only included the first episodes of GNB bacteremia, however as the resistance could increase with the number of episodes it could be interesting to evaluate the use of the test in the second, third or even more episodes of bacteremia.
In conclusion, in a situation of ESBL-E emergence, BLT, when combined with MALDI-TOF MS and real-time advice from the AMST, did not contribute significantly, in our institution, to the optimization of antimicrobial therapy and, in particular, carbapenem prescription. The impact of BLT would merit to be evaluated more widely in a population of patients with high prevalence of ESBL-producing Enterobacteriaceae and/or in institutions or situations where treatment choices are not made by infectious disease specialists.
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